Skip to main content
US EQUITIES OPEN CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
TN

TNXPStock

Nasdaq Global Select Market · Healthcare

$2.73 last close 2026-11-19
Open in terminalCompare
Price alert

Verdicts genuinely change. Free email alert the moment TNXP's does — no target price to set, unlike a price alert.

Stable Ratio screen, 0 of 7 decided standards passing. No standard's deciding ratio sits within 3 points of its line. What would change it

Sharia status
NOT COMPLIANT
Per our in-house ratio engine
0 of 7 pass our own screen — all 7 agree here
Purification 100.00% *HTR non-permissible income 31.63%
🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No trade setup shown — a stock that isn't cleanly Sharia-compliant never gets a bullish verdict here.

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure0 of 5 timeframes bullish · 100.0% aligned
VWAPPrice below VWAP ($2.93)
VolumeRelative volume 4.3× the 20-day average
Momentum10-day rate of change -40.8%

TNXP is currently considered not halal (non-compliant), per our in-house ratio engine. See the full ratio breakdown and business-activity screen below for the reasoning.

⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.

434 other Healthcare stocks pass this same screen. See compliant Healthcare stocks →

Market & analysts
Price target
$31.60
+1059.6% · 5 analysts
Institutional own.
53.2%
of shares
Momentum (10d)
-40.8%
rate of change
SMC grade
C · 53
100.0% aligned
100.00% *
Purification ratio (secondary provider, uncertain)
31.63%
Non-permissible income — HTR, from filings (2025-12-31)
C · 53
SMC grade — 100.0% timeframe alignment
-40.8%
Rate of change (10d)
$31.60
Price target (+1059.6%) · 5 analysts
53.2%
Institutional ownership

How the status reached this point

Non-compliant · status tracked since Nov 17, 2026

No change to TNXP’s published status has been recorded since our daily status check began on Nov 17, 2026. What it read before then is not on record here.

Read once a day from our own screen, last on Nov 18, 2026. The per-methodology record is under “What changed, and when” in the in-house research.

Free email, sent when our compliance re-scan finds a change.

🕌 In-house Compliance Research

Computed from published company financials, balance sheet as of 2026-09-30. These ratios come from the issuer's own published statements rather than structured SEC data.

AAOIFI divides by the market cap: $54.8M as of 2026-11-19.

Business activity: cleared (no excluded categories detected)

AAOIFI Fail 0 of 2 ratios pass
RatioValueThresholdResult
Interest-bearing investments 297.79% 30.00% Fail(267.8pp over)
Non-permissible income 31.63% 5.00% Fail(26.6pp over)
Usmani Fail 1 of 3 ratios pass
RatioValueThresholdResult
Interest-bearing investments 67.31% 33.00% Fail(34.3pp over)
Non-liquid assets 26.67% at least 20.00% Pass(6.7pp above the floor)
Non-permissible income 31.63% 5.00% Fail(26.6pp over)
MSCI Fail 0 of 3 ratios pass
RatioValueThresholdResult
Cash + interest-bearing securities 67.31% 33.33% Fail(34.0pp over)
Accounts receivable 73.33% 33.33% Fail(40.0pp over)
Non-permissible income 31.63% 5.00% Fail(26.6pp over)
FTSE Fail 0 of 3 ratios pass
RatioValueThresholdResult
Cash + interest-bearing securities 67.31% 33.33% Fail(34.0pp over)
Accounts receivable 73.33% 50.00% Fail(23.3pp over)
Non-permissible income 31.63% 5.00% Fail(26.6pp over)
Dow Jones Islamic Market Fail 1 of 3 ratios pass

Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Cash + interest-bearing securities 83.95% 33.00% Fail(51.0pp over)
Accounts receivable 7.51% 33.00% Pass(25.5pp buffer)
Non-permissible income 31.63% 5.00% Fail(26.6pp over)
S&P Shariah Fail 1 of 3 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Cash + interest-bearing securities 122.11% 49.00% Fail(73.1pp over)
Accounts receivable 10.92% 49.00% Pass(38.1pp buffer)
Non-permissible income 31.63% 5.00% Fail(26.6pp over)
MSCI M-Series Fail 0 of 3 ratios pass

Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.

RatioValueThresholdResult
Cash + interest-bearing securities 122.11% 33.33% Fail(88.8pp over)
Accounts receivable 133.04% 49.00% Fail(84.0pp over)
Non-permissible income 31.63% 5.00% Fail(26.6pp over)

Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.

How close is it to flipping?

Every current reading against its own line, closest first. A verdict is only as durable as that distance.

Usmani (% of total assets)nonliquid assets ratio · floor 6.7pts
Dow Jones Islamic Market (% of 24-mo avg market cap)receivables ratio 25.5pts
S&P Shariah Indices (% of 36-mo avg market cap)receivables ratio 38.1pts
AAOIFI Standard 21 (% of market cap)investments ratio 267.8pts
MSCI Islamic M-Series (% of 36-mo avg market cap)cash and interest ratio 88.8pts
MSCI Islamic M-Series (% of 36-mo avg market cap)receivables ratio 84.0pts

The numbers the ratios are built from

Read from TNXP's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.

LineFigureAs reportedRead from
RevenueTotal revenue for the period $13.1M 2025-12-31 RevenueFromContractWithCustomerExcludingAssessedTax
Interest-bearing debtBorrowings — which definition was stored is not recorded not measured — —
Cash and interest-bearing securitiesCash, equivalents and marketable securities $163.2M 2026-09-30 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
Total assetsBalance sheet total $242.4M 2026-09-30 Assets
Market capDenominator for AAOIFI $54.8M live quote price x shares
36-month average market capDenominator for S&P Shariah and MSCI M-Series $117.8M 756 trading days closes x shares
24-month average market capDenominator for Dow Jones Islamic Market $172.7M 504 trading days closes x shares
Non-permissible revenueInterest and excluded income $4.1M 2025-12-31 InvestmentIncomeInterest

Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.

Sources

Filing information. Balance sheet: Quarterly report (10-Q) filed 2026-11-09, period ended 2026-09-30. Income statement: Annual report (10-K) filed 2026-03-12, period ended 2025-12-31. Screened 2026-11-19.

  • Total assets$242.4M
    Assets · period ended 2026-09-30 · 10-Q filed 2026-11-09
  • Cash and interest-bearing securities$163.2M
    CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · period ended 2026-09-30 · 10-Q filed 2026-11-09
  • Receivables$14.6M
    AccountsReceivableNetCurrent · period ended 2026-09-30 · 10-Q filed 2026-11-09
  • Revenue$13.1M
    RevenueFromContractWithCustomerExcludingAssessedTax · period ended 2025-12-31 · 10-K filed 2026-03-12
  • Interest income (non-permissible)$4.1M
    InvestmentIncomeInterest · period ended 2025-12-31 · 10-K filed 2026-03-12
  • Market cap$54.8M
    Market quote passed in by the screen (Finnhub company profile; Yahoo Finance where Finnhub has none), 2026-11-19 · not a filing figure, so no link

5 reported values cited from 2 SEC filings, read from SEC's XBRL company facts when this symbol was screened. A link opens the filing's index on EDGAR.

What changed, and when

Verdict history for TNXP. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.

  • 2026-11-15 Unverified → Fail filing re-screen

Tracked since 2026-09-07.

What would change the status

The headline verdict is the majority of the decided ratio standards — 0 pass and 7 fail of 7 — with a business-activity screen and any hold applied on top. Balance sheet as of 2026-09-30; market cap as stored on 2026-11-19.

No standard's deciding ratio sits within 3 points of its line.

The ratios that move with the share price

AAOIFI's investments ratio is $163.2M cash and interest-bearing investments over a market cap of $54.8M (as of 2026-11-19), 297.8% against a 30% line.

It would pass if the market cap rose above $543.9M (+893%), about $27.99 a share against $2.82 implied by the screen's own figures.

AAOIFI would then fail; the majority verdict would stay Not compliant (0 of 7 decided standards passing).

At the screen's market cap, it would take $146.7M less cash and interest-bearing investments to clear the line.

AAOIFI would then fail; the majority verdict would stay Not compliant (0 of 7 decided standards passing, counting every standard that divides the same figure).

Only AAOIFI divides by the market cap itself. The Dow Jones, S&P and MSCI M-Series standards divide by a 24- or 36-month average and the others by total assets, so a day's price move does not reach them. Figures are the screen's own; the live market cap differs from the stored one.

Shariah-compliant alternatives

Compliant companies in Biotechnology listed on the same market, largest first. Each is screened on its own; none carries a documented concern or a hold.

CompanyMarket capPrice, day
VRTXVertex Pharmaceuticals, Inc. $121.1B —
REGNRegeneron Pharmaceuticals, Inc. $85.3B —
ARGXArgen X SE - ADR $64.3B —
ONCBeOne Medicines Ltd. American Depositary Shares $40.4B —
ALNYAlnylam Pharmaceuticals Inc $31.6B —

A dash means no fresh quote is cached for that symbol; this list does not fetch one.

Funds that hold TNXP

2 of the 202 funds whose filed holdings we currently hold own TNXP shares. That set is a fixed list of widely held index funds and Shariah funds, plus the funds our look-through has read most recently. It is not every fund that owns TNXP.

You may already own it

Widely held U.S. index funds. If you own one, you own TNXP through it. None of them is a Shariah fund; the last column is our look-through of each.

FundTNXP in fundFund compliant by weight
VTI VANGUARD TOTAL STOCK MARKET INDEX FUND 0.00% 54%
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00% 54%

Sorted by TNXP’s share of each fund, from the fund’s latest SEC N-PORT filing. “Compliant by weight” is the share of the fund’s holdings our look-through screens compliant. A fund is listed only where its filing is mostly equity and names TNXP once, so a bond is not counted as the shares. Shariah funds are those with a recorded certification, on our halal ETF list, or named Shariah, Islamic, Halal or Sukuk.

Tracked investors holding TNXP
InvestorFirmPositionWeightAs of
Steven Cohen Point72 Asset Management $11M 0.0% 2026-09-30
Israel Englander Millennium Management $8M 0.0% 2026-09-30
Ken Griffin Citadel Advisors $4M 0.0% 2026-09-30
David Shaw D. E. Shaw & Co. $0M 0.0% 2026-09-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

19.8915.6011.327.032.742025-11-192026-05-222026-11-19

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
2.52
S2
2.65
S1
2.73
PIVOT
2.86
R1
2.94
R2
3.07
R3
3.15

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
8.32 – 11.34
±15.34% from 9.83, made 2026-09-30 · resolves 2026-10-07
STRONG SELL
from 19 indicators
78.7% of our last 25417 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 53.4% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

STRONG SELL
19 indicators
OscillatorsBUY
4 buy · 0 neutral · 3 sell
Moving averagesSTRONG SELL
0 buy · 0 neutral · 12 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)11.90BUY
Stochastic %K (14)0.94BUY
CCI (20)-122.13BUY
Williams %R (14)-99.06BUY
MACD (12,26,9)-0.02SELL
ROC (10)-40.33SELL
Momentum (10)-1.86SELL
EMA (10)3.43SELL
SMA (10)3.48SELL
EMA (20)4.26SELL
SMA (20)4.32SELL
EMA (30)5.07SELL
SMA (30)4.92SELL
EMA (50)6.44SELL
SMA (50)6.92SELL
EMA (100)8.61SELL
SMA (100)9.52SELL
EMA (200)11.10SELL
SMA (200)11.51SELL

About TNXP

Healthcare · Biotechnology

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.

tonixpharma.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Grade verdict

Average — needs more confirmation before sizing up

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BEARISH 44
⏰ 4H BEARISH 44
🕐 1H BEARISH 98
⏱ 15-Min BEARISH 130
⏲ 5-Min BEARISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

-40.8%
Rate of change (10d)
4.3×
Volume vs its 20-day average
-1.22
MACD (BULLISH)
$2.80
Volume POC (today)
$2.75 – $2.83
Value area

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-11-10 · Asset managers net 914130 (-14454)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.